Androgen suppression (AS) used prior to or following RT for locally advanced prostate cancer reduces cancerous recurrence in the prostate and at metastatic sites, thereby also reducing prostate cancer mortality. 

AS durations of 2 or more years have been shown to produce the greatest reductions but also cause many unwanted side effects. Two important prescribing questions remain unanswered:

  1. The optimal duration of AS 
  2. The concurrent use of other therapeutic agents, such as zoledronate, which can help to reverse AS induced osteopenia as well as prevent bone metastases. While not duplicating other international trial efforts, the RADAR trial addresses these issues in a 2X2 factorial design.


Research Area 
Project type 
Project Grant
Year of funding